Lipase For Diarrhea Clinical Trial

Evidence-based review of published clinical trials, dosage data, and what lipase can — and cannot — do for diarrhea symptoms

---

Table of Contents

1. What This Article Covers (And Why It Matters)
2. What Is Lipase and How Does It Relate to Diarrhea?
3. The Clinical Trial Evidence: A Full Review
4. IBS-D Pilot Trial: The 2011 Pancrealipase Study
5. Persistent Diarrhea in Children: The 2018 Trial
6. EPI Trials: Stool Frequency and Steatorrhea Data
7. RELiZORB and Immobilized Lipase: Emerging Trial Data
8. Does Lipase Help Diarrhea Without Pancreatic Disease?
9. Lipase vs. Pancrealipase: Understanding the Difference
10. Lipase Dosage for Diarrhea: What Clinical Trials Used
11. Side Effects and Safety Data From Trials
12. Natural Lipase, Lipase Extracts, and Lipase Tea for Diarrhea
13. How to Choose the Best Lipase Supplement for Diarrhea
14. Active and Enrolling Trials: What Is Coming Next
15. Frequently Asked Questions
16. Clinical Summary and Key Takeaways

---

1. What This Article Covers (And Why It Matters)

If you have searched for a lipase for diarrhea clinical trial, you have likely encountered one of two frustrating results: either vague supplement marketing that cites no real science, or dense academic papers written for gastroenterologists, not patients or caregivers.

This article bridges that gap.

What you will find here is a complete, plainly written synthesis of every major peer-reviewed clinical trial that has tested lipase or pancrealipase as a treatment for diarrhea — including the specific patient populations studied, the exact statistics reported, the dosages used, and the honest limitations of what the science currently supports.

The short answer to whether lipase stops diarrhea is nuanced: it depends entirely on why the diarrhea is happening. When diarrhea is driven by fat malabsorption caused by insufficient pancreatic enzyme activity — as in Exocrine Pancreatic Insufficiency (EPI), certain cases of IBS-D, or persistent diarrhea linked to malnutrition — the clinical evidence is meaningful. When diarrhea has other causes, such as infection or inflammatory bowel disease unrelated to fat digestion, the evidence does not support lipase supplementation as a primary remedy.

Understanding that distinction is the entire purpose of this review.

---

---

2. What Is Lipase and How Does It Relate to Diarrhea?

Lipase is a digestive enzyme produced primarily by the pancreas. Its core function is to break down dietary fats — specifically triglycerides — into fatty acids and monoglycerides that can be absorbed through the wall of the small intestine.

When the pancreas produces insufficient lipase, or when lipase delivery to the small intestine is disrupted, dietary fats pass undigested into the large intestine. Gut bacteria ferment these unabsorbed fats, producing gas, cramping, and notably, steatorrhea — loose, greasy, foul-smelling stools that are one of the hallmark symptoms of fat malabsorption.

This is the physiological basis for the connection between lipase diarrhea: when lipase is deficient or dysfunctional, diarrhea characterized by fatty stools and urgency frequently results.

Key conditions where lipase insufficiency causes diarrhea include:

• Exocrine Pancreatic Insufficiency (EPI): The pancreas fails to produce adequate digestive enzymes. EPI is seen in chronic pancreatitis, cystic fibrosis, pancreatic cancer, and following pancreatic surgery.
• IBS with Diarrhea (IBS-D): A subset of IBS-D patients have measurable fat malabsorption triggered by meals, suggesting a lipase-related component to their postprandial symptoms.
• Persistent Diarrhea in Children: Malnutrition-associated diarrhea in children can involve impaired pancreatic enzyme secretion, reducing fat absorption efficiency.

Understanding this mechanism is essential before evaluating any lipase diarrhea supplement, because supplemental lipase only addresses diarrhea when fat malabsorption is part of the underlying problem.

---

3. The Clinical Trial Evidence: A Full Review

Before examining each individual study, it is important to state clearly what the current clinical trial landscape looks like for this topic.

There are no established clinical trials that test lipase alone as a treatment for general, non-specific diarrhea. This is not a gap in research funding — it reflects the biology. Lipase corrects diarrhea caused by fat maldigestion. It does not have a plausible mechanism for treating diarrhea caused by viruses, bacteria, inflammatory cytokines, bile acid malabsorption, or motility disorders unrelated to fat digestion.

The clinical trials that do exist test pancrealipase — a standardized formulation containing lipase alongside amylase and protease — in patients with clearly documented fat malabsorption-related diarrhea. These trials are randomized, placebo-controlled, and peer-reviewed.

Here is a master summary of the four main trial datasets reviewed in this article:

| Study Population | Intervention | Key Finding | Year | |---|---|---|---| | IBS-D (postprandial) | Pancrealipase (PEZ) vs. placebo | 61% patient preference for PEZ; all symptoms improved (p≤0.001) | 2011 | | Persistent diarrhea in children | Pancreatic enzyme supplementation vs. placebo | Diarrhea duration shortened by 7 days (p=0.019) | 2018 | | EPI (stool frequency) | Pancrelipase vs. placebo | 1.2 fewer stools per day; 33% more patients achieved normal stools | Post-2018 | | Enteral nutrition patients | RELiZORB immobilized lipase | 68% reduction in diarrhea incidence in 24-hour study (p<0.001); 0% diarrhea incidence at Day 90 (p<0.001) | NCT03530852 |

Each of these trials is examined in detail below.

---

4. IBS-D Pilot Trial: The 2011 Pancrealipase Study

Study Design and Patient Population

The most directly relevant lipase for diarrhea clinical trial for adult patients with IBS-D is the randomized, double-blind, placebo-controlled pilot study published in Functional Gastroenterology (PMC3009417). This is one of the few trials that specifically examined whether pancrealipase could reduce postprandial diarrhea symptoms in patients who did not have a formal diagnosis of EPI but did have fat malabsorption as a contributing factor to their IBS-D symptoms.

The study enrolled 49 patients with confirmed IBS-D according to Rome III diagnostic criteria. Participants had documented postprandial symptoms — meaning their diarrhea, cramping, bloating, and urgency were reliably triggered by eating. The trial used a crossover design, meaning each patient received both pancrealipase (branded PEZ) and an identical-appearing placebo in randomized order, allowing within-subject comparisons.

Key Statistics

The results of this pilot trial are frequently cited in discussions of lipase and diarrhea relief, and for good reason:

• 61% of patients (30 out of 49) preferred pancrealipase over placebo when asked which treatment period felt better overall.
• The first-drug preference for pancrealipase reached statistical significance at p=0.002, meaning patients who received pancrealipase first rated their symptoms significantly better than those who received placebo first.
• The overall preference trend approached but did not reach conventional significance (p=0.078), which is expected for a pilot trial of this sample size.
• In the subgroup of patients who received pancrealipase, all four measured symptoms — abdominal cramping, bloating, urgency to defecate, and stooling frequency — improved significantly compared to placebo at p≤0.001.
• Pancrealipase increased stool firmness compared to placebo.
• No serious adverse events were recorded in either group.

What This Trial Tells Us

This study is important precisely because it was conducted in IBS-D patients, not EPI patients. It suggests that a measurable subgroup of people with diarrhea with lipase deficiency — even subclinical deficiency not meeting EPI criteria — may experience meaningful symptom relief from enzyme replacement.

However, the authors are careful to note this was a pilot study. The sample size of 49 patients is relatively small. The p=0.078 for overall preference does not cross the conventional p<0.05 threshold, and the authors explicitly call for larger confirmatory trials. No such large-scale confirmatory trial has been published as of the writing of this article.

The clinical takeaway is cautious optimism: pancrealipase showed biologically plausible and statistically significant improvement in specific symptom measures for IBS-D patients, particularly those whose symptoms are postprandial and consistent with fat malabsorption.

---

5. Persistent Diarrhea in Children: The 2018 Trial

Study Design and Patient Population

The second major trial came from the Asian Pacific Journal of Clinical Nutrition (APJCN) in 2018. This randomized clinical trial evaluated the effects of pancreatic enzyme supplementation on persistent diarrhea in children, a condition defined as diarrhea lasting more than 14 days and strongly associated with malnutrition in developing-country contexts.

Persistent diarrhea in children often involves a secondary impairment of pancreatic enzyme secretion due to malnutrition, creating a cycle where malabsorption perpetuates nutritional deficits, which further impairs enzyme production. The hypothesis of this trial was that supplementing with pancreatic enzymes — including lipase — could break that cycle and shorten diarrhea duration.

Key Statistics

• The intervention group receiving pancreatic enzyme supplementation experienced a diarrhea duration that was 7 days shorter than the placebo group (p=0.019).
• This is a clinically meaningful result. Seven days represents a substantial reduction in a condition that, by definition, has already lasted more than two weeks.
• Serum prealbumin (a marker of nutritional status) and Fecal Elastase-1 (FE-1, a marker of pancreatic exocrine function) both showed trends favoring the intervention group, though these trends did not reach statistical significance (p>0.05).
• The non-significant nutritional markers suggest that while enzyme supplementation helped resolve diarrhea faster, it may not have been sufficient alone to fully restore pancreatic function or nutritional status within the trial timeframe.

What This Trial Tells Us

This 2018 study adds an important dimension to understanding lipase benefits diarrhea: the benefit is not limited to adults with formal EPI diagnoses. Children with malnutrition-associated diarrhea, who have secondary enzyme insufficiency, also appear to benefit from enzyme supplementation — at least in terms of resolving diarrhea faster.

The fact that nutritional markers did not reach significance is a reminder that lipase supplementation addresses a symptom (diarrhea caused by fat malabsorption) without necessarily correcting the underlying nutritional or pancreatic causes. It should be considered part of a broader nutritional rehabilitation strategy in children rather than a standalone solution.

---

---

6. EPI Trials: Stool Frequency and Steatorrhea Data

The EPI Patient Population

Exocrine Pancreatic Insufficiency is the condition where the evidence for diarrhea with lipase supplementation is strongest and most consistently replicated. In EPI, the pancreas fails to produce sufficient digestive enzymes — including lipase — and the result is predictable: undigested fat floods the colon, producing steatorrhea, frequent loose stools, urgency, bloating, and significant weight loss.

Pancreatic Enzyme Replacement Therapy (PERT) — the clinical name for pancrealipase formulations given to EPI patients — has been studied in multiple randomized controlled trials. The data cited here represents pooled findings from post-2018 EPI trials using pancrelipase.

Key Statistics

• Pancrelipase reduced mean stool frequency by 1.2 stools per day compared to placebo in randomized EPI trials.
• 33% more patients in the pancrelipase group achieved normal or formed stools compared to the placebo group.
• Watery stools were eliminated in the pancrelipase group — a notable finding, because watery stool (versus fatty/greasy stool) in EPI suggests a degree of malabsorption beyond fat alone.
• These improvements were accompanied by increases in fat absorption coefficients, confirming that the mechanism of action — improved fat digestion — translated directly into symptom improvement.

Steatorrhea Resolution: The Dosage Threshold

One of the most clinically actionable findings from EPI trial data concerns the dose required to resolve steatorrhea (fatty diarrhea). Research suggests that 18,000 to 30,000 USP units of lipase per meal are needed to adequately resolve steatorrhea when lipase is delivered correctly to the small intestine.

This dosage figure is important for several reasons:

1. It is substantially higher than the lipase content of most over-the-counter digestive enzyme supplements.
2. It refers specifically to delivery to the small intestine — enteric coating or timing relative to meals matters significantly.
3. It applies to patients with EPI or measurable fat malabsorption, not to general diarrhea without that underlying mechanism.

---

7. RELiZORB and Immobilized Lipase: Emerging Trial Data

What Is RELiZORB?

RELiZORB represents a different and technically innovative approach to lipase supplementation. Rather than oral capsules containing lipase that must survive stomach acid and reach the small intestine, RELiZORB is an immobilized lipase cartridge used inline with enteral feeding tubes. The cartridge contains lipase that is physically attached to a solid support matrix, allowing the enzyme to act on enteral nutrition formula as it passes through the tube — essentially pre-digesting the fat before it enters the patient's GI tract.

This approach was developed specifically for patients on enteral nutrition (tube feeding) who have EPI or fat malabsorption, and who cannot reliably take or absorb oral enzyme capsules.

Clinical Trial Data (NCT03530852)

The trial data for RELiZORB immobilized lipase is among the most dramatic in this entire field:

• In a 24-hour study, RELiZORB produced a 68% reduction in diarrhea incidence compared to control (P<0.001).
• In a 90-day study, the reported incidence of diarrhea reached 0% in the RELiZORB group at Day 90 (P<0.001).

These are extraordinary numbers by any clinical standard. The 0% diarrhea incidence at Day 90 is particularly notable, though it must be interpreted in context: these are patients on enteral nutrition with fat malabsorption, for whom every unit of lipase delivered via the cartridge directly addresses the mechanism causing their diarrhea. The baseline diarrhea incidence in this population on standard enteral feeding is high, which makes the magnitude of improvement possible.

What This Tells Us About Lipase Extract and Delivery

The RELiZORB data reinforces a key principle for understanding lipase extract diarrhea applications broadly: delivery mechanism matters as much as dose. Lipase that reaches fat in the small intestine in an active form will produce meaningful clinical benefits in fat malabsorption-driven diarrhea. Lipase that is degraded by stomach acid before reaching the small intestine will produce minimal benefit regardless of the dose consumed.

This is why enteric-coated pancrealipase capsules were developed for EPI, and why immobilized cartridge technology was developed for enteral nutrition patients. It also has implications for anyone evaluating an oral lipase diarrhea supplement: enteric coating, enzyme activity units (not just milligram content), and timing relative to meals are all critical variables.

---

8. Does Lipase Help Diarrhea Without Pancreatic Disease?

This is the question most people searching for "lipase for diarrhea clinical trial" actually want answered, and it deserves a direct, evidence-based response.

Current clinical trial evidence does not support using lipase to treat diarrhea in people without underlying fat malabsorption or pancreatic insufficiency.

Here is the reasoning:

Lipase reduces diarrhea by improving the digestion and absorption of dietary fats. When fat is properly absorbed, less undigested fat reaches the colon, and the secondary diarrhea, cramping, and urgency caused by fat fermentation in the colon is reduced.

If your diarrhea is caused by something that has nothing to do with fat malabsorption — a viral gastroenteritis, Clostridioides difficile infection, bile acid malabsorption, microscopic colitis, lactose intolerance, or pure motility disorders — adding lipase to your regimen will not address the mechanism driving your symptoms.

The one partial exception in the current trial data is the IBS-D pilot study discussed above. That trial enrolled IBS-D patients without confirmed EPI, and a meaningful 61% preferred pancrealipase. This suggests there is a subgroup of IBS-D patients who have subclinical fat malabsorption contributing to their postprandial symptoms, and who may benefit from enzyme supplementation. But this is not the same as saying "lipase helps diarrhea in everyone without pancreatic disease." It means that within IBS-D, a subset with fat malabsorption as a contributing factor may benefit.

If you have chronic, unexplained diarrhea, especially if it is postprandial, fatty, or associated with weight loss, a clinician evaluation for EPI (including fecal elastase testing) is warranted before self-supplementing.

---

9. Lipase vs. Pancrealipase: Understanding the Difference

One of the most common points of confusion when researching this topic is the distinction between lipase (a single enzyme) and pancrealipase (a multi-enzyme formulation). This distinction matters clinically.

Lipase Alone

Lipase is a single enzyme that catalyzes the hydrolysis of triglycerides. Standalone lipase supplements — often derived from fungal or plant sources such as Aspergillus niger or Rhizopus oryzae — contain only this one enzymatic activity.

In the context of fat malabsorption, lipase alone may partially address the problem, but fat digestion also requires:

• Colipase (a cofactor for pancreatic lipase that is not present in fungal lipase preparations)
• Bile salts (to emulsify fat before lipase can act)
• Adequate gastric acid and duodenal pH for optimal enzyme activity

Pancrealipase (PERT)

Pancrealipase is a pancreatic enzyme replacement formulation containing a standardized mixture of:

• Lipase (the fat-digesting component)
• Amylase (for starch digestion)
• Protease (for protein digestion)

This formulation — sold under brand names such as Creon, Zenpep, Pancreaze, and others — more closely replicates the full enzymatic output of a healthy pancreas. All of the clinical trials reviewed in this article used pancrealipase formulations rather than isolated lipase, which is an important nuance when evaluating whether a standalone lipase diarrhea supplement would produce equivalent results.

The honest answer is: we do not know whether isolated lipase would produce the same benefits as pancrealipase in EPI or IBS-D, because no head-to-head trials have been conducted. The trials used pancrealipase. Extrapolating those results to standalone lipase supplements is a logical step but not a proven equivalence.

---

10. Lipase Dosage for Diarrhea: What Clinical Trials Used

Understanding lipase dosage diarrhea recommendations requires separating what clinical trials used from what is typically found in OTC supplements.

Doses Used in Clinical Trials

| Study | Lipase Dose | Formulation | Timing | |---|---|---|---| | IBS-D Pilot (2011) | Variable (PEZ proprietary dose) | Pancrealipase capsules | With meals | | Persistent Diarrhea Children (2018) | Pediatric weight-based dosing | Pancreatic enzyme supplement | With meals | | EPI Trials (post-2018) | 18,000–72,000 USP lipase units per meal | Enteric-coated pancrealipase | With meals | | RELiZORB (NCT03530852) | Cartridge-based (continuous) | Immobilized lipase | During enteral feeding |

The 18,000–30,000 USP Unit Threshold

As referenced in the EPI data, the clinical evidence suggests 18,000 to 30,000 USP units of lipase per meal as a starting threshold for resolving steatorrhea in EPI. For snacks, approximately half that amount (9,000–15,000 USP units) is typically recommended.

Prescription PERT formulations like Creon 24,000 contain 24,000 USP lipase units per capsule, positioned squarely in this therapeutic range.

What OTC Supplements Typically Contain

By comparison, most commercially available OTC digestive enzyme supplements contain between 5,000 and 12,000 FIP units (a different unit of measurement) or 500 to 2,000 USP units of lipase per serving. This is substantially below the doses used in EPI clinical trials.

For patients with mild, subclinical fat malabsorption — such as the IBS-D patients in the 2011 pilot — lower doses may still provide benefit, which is why the IBS-D results are not necessarily contradicted by this dosage gap. But for patients with confirmed EPI or significant steatorrhea, OTC supplement doses are almost certainly insufficient.

---

11. Side Effects and Safety Data From Trials

One of the reassuring findings across all the clinical trials reviewed is the consistent safety profile of pancrealipase/lipase supplementation.

Reported Side Effects

From the 2011 IBS-D Pilot Trial:

• No serious adverse events were recorded in either the pancrealipase or placebo group.
• Minor adverse effects observed in some participants included increased flatulence and, in a small number, mild constipation — the latter reflecting that the treatment was effective enough at reducing diarrhea that stools became more formed, occasionally overshooting the desired consistency.

From EPI Trials Generally:

• The most commonly reported side effects of pancrealipase in EPI patients are abdominal discomfort, nausea, and increased gas, all typically mild and dose-dependent.
• A rare but serious concern with very high-dose PERT (above 10,000 USP lipase units per kilogram per day) in cystic fibrosis patients is fibrosing colonopathy — a thickening and scarring of the colon wall. This has been reported almost exclusively in pediatric cystic fibrosis patients on exceptionally high doses and is not a concern at standard therapeutic doses in adults.

From the 2018 Children's Trial:

• The trial reported no significant adverse events in either the enzyme supplementation or placebo group.

The Safety Bottom Line

At doses used in clinical trials — and particularly at OTC supplement doses — lipase and pancrealipase have a favorable safety profile. The absence of serious adverse events across multiple randomized controlled trials is a meaningful finding, supporting the use of enzyme supplementation in appropriately identified patients without significant safety concern.

---

12. Natural Lipase, Lipase Extracts, and Lipase Tea for Diarrhea

Because many people searching this topic are interested in natural lipase diarrhea approaches, it is worth addressing the evidence — and the limitations — for natural enzyme sources.

Natural Food Sources of Lipase

Several foods contain naturally occurring lipase activity:

• Raw milk and raw dairy products: Contain naturally occurring lipase that is typically destroyed by pasteurization.
• Avocados: Contain lipase-like lipolytic activity.
• Fermented foods: Miso, kefir, and aged cheeses contain microbially produced lipase.
• Raw wheat germ: Contains lipase activity.
• Certain germinated seeds and sprouts: Germination activates endogenous lipase enzymes in seeds.

However, it is critical to understand that consuming these foods does not deliver a therapeutically meaningful dose of lipase to your small intestine for two reasons: first, the lipase activity in foods is far below clinical trial doses; and second, much of the lipase activity is degraded by stomach acid and heat during eating and digestion.

There are no clinical trials demonstrating that food-sourced natural lipase reduces diarrhea.

Lipase Extract for Diarrhea

Lipase extract diarrhea products — typically fungal-derived lipase from Aspergillus species — are sometimes marketed as more "natural" alternatives to porcine-derived pancrelipase. Fungal lipase has the practical advantage of being active at a wider pH range than pancreatic lipase, which means it may survive stomach acid better.

However, fungal lipase extracts lack colipase (a required cofactor for fat digestion), and they have not been tested in the same rigorous clinical trials as pancrealipase. Their use in clinical settings remains off-label and theoretical rather than trial-validated.

Lipase Tea for Diarrhea

Lipase tea diarrhea is a term that appears in some natural health spaces, typically referring to teas made from herbs traditionally used for digestive support, such as ginger, dandelion root, or fenugreek. While some of these herbs have demonstrated digestive benefits in small studies, none have been shown to deliver meaningful lipase activity or to specifically address fat malabsorption-driven diarrhea.

The term "lipase tea" has no established clinical meaning. Any beneficial effects of such teas on diarrhea are more likely attributable to their anti-inflammatory, bile-stimulating, or gut motility effects than to lipase activity per se.

The honest assessment: If you are dealing with diarrhea that may have a fat malabsorption component, the evidence supports standardized enzyme formulations over food sources or herbal teas. Natural approaches may offer complementary digestive support but should not be expected to replicate the clinical trial results seen with pancrealipase.

---

---

13. How to Choose the Best Lipase Supplement for Diarrhea

Given everything the clinical trial evidence shows, what should someone look for when evaluating lipase benefits diarrhea claims on supplement labels?

What to Look For in the Best Lipase for Diarrhea

1. Lipase Activity Units, Not Just Milligrams

Enzyme potency is measured in activity units, not weight. For lipase, look for USP units (United States Pharmacopeia), FIP units (International Federation of Pharmacy), or LU (Lipase Units). A product listing only milligrams of "lipase enzyme" without activity units cannot be evaluated for potency.

2. Enteric Coating (for Fat Malabsorption)

If your goal is to address fat malabsorption-driven diarrhea, enteric-coated capsules — which protect enzyme activity through the acidic stomach and release in the alkaline small intestine — are strongly preferable to non-coated capsules. This mirrors the formulation design of all pancrealipase products tested in clinical trials.

3. Multi-Enzyme Formulations

As discussed above, all clinical trials used pancrealipase — containing lipase, amylase, and protease together. Multi-enzyme formulations more closely approximate the studied interventions. A broad-spectrum digestive enzyme product that includes meaningful lipase activity alongside amylase and protease is more aligned with the evidence base than standalone lipase.

4. Third-Party Testing

Look for supplements that disclose third-party testing for potency and purity. Enzyme activity in supplements can degrade with improper storage or manufacturing. NSF, USP, or ConsumerLab verification is a meaningful quality signal.

5. Dose Aligned With Intended Use

For mild postprandial fat intolerance or IBS-D support, OTC doses in the 5,000–12,000 FIP/lipase unit range may provide modest support. For documented fat malabsorption or EPI, prescription PERT at 18,000–72,000 USP units per meal under physician supervision is the evidence-based standard.

6. Source of Lipase

Porcine-derived (pig pancreas) pancrealipase most closely matches the enzymatic profile studied in clinical trials. For vegetarian or kosher/halal requirements, fungal-derived lipase is available but has a different activity profile and less clinical trial support.

A Word on Marketing Claims

Be cautious of any supplement claiming to "stop diarrhea" through lipase without specifying the mechanism. As established throughout this article, lipase only addresses diarrhea caused by fat malabsorption. Products making generalized anti-diarrheal claims for lipase are extrapolating beyond what the clinical evidence supports.

---

14. Active and Enrolling Trials: What Is Coming Next

Current State of the Research Pipeline

As of the writing of this article, no peer-reviewed results from clinical trials specifically designed around "lipase for diarrhea" as a primary endpoint have been published between 2024 and 2026. The most recent published data remains the 2018 pediatric trial and the 2011 IBS-D pilot.

However, several important research directions are active:

RELiZORB and Immobilized Lipase Expansion Clinical trials for RELiZORB immobilized lipase (NCT03530852 and related protocols) have been actively enrolling or open for patients with Exocrine Pancreatic Insufficiency on enteral nutrition. Given the dramatic results in existing data (68% reduction in 24-hour diarrhea incidence, 0% at Day 90), larger confirmatory trials and expanded indications are anticipated.

IBS-D Confirmatory Trials The 2011 pilot trial explicitly called for larger randomized controlled trials to confirm its findings. As of 2024, no such large-scale confirmatory IBS-D trial result has been published, representing a significant gap in the evidence base for natural lipase diarrhea and enzyme supplement applications in non-EPI populations.

EPI Diagnosis and PERT Optimization Ongoing research is focused on improving EPI diagnosis rates (it is believed to be substantially underdiagnosed) and optimizing PERT dosing strategies, particularly in chronic pancreatitis and post-surgical populations.

Pediatric EPI Enzyme supplementation in pediatric populations — beyond the persistent diarrhea context studied in the 2018 trial — is an active area, particularly in cystic fibrosis and pediatric pancreatitis.

What Patients and Clinicians Are Waiting For

The single most impactful unpublished trial result would be a large-scale (n>200), well-powered, randomized controlled trial of pancrealipase versus placebo in IBS-D patients stratified by fat malabsorption biomarkers. Such a trial would either confirm the 2011 pilot findings at statistical confidence or clarify the limits of enzyme supplementation in IBS-D. Until that trial is conducted and published, the 2011 pilot remains the best available evidence for this population.

---

15. Frequently Asked Questions

Does lipase stop diarrhea in people without pancreatic disease?

No clinical trial evidence supports this. The trials reviewed here enrolled patients with EPI, IBS-D (with probable fat malabsorption), or malnutrition-associated persistent diarrhea. Lipase reduces diarrhea by improving fat digestion — if your diarrhea has a different cause, lipase supplementation is unlikely to help and the evidence does not support it as a general anti-diarrheal.

What is the difference between lipase and pancrealipase?

Lipase is a single enzyme that breaks down triglycerides. Pancrealipase is a formulation containing lipase, amylase (starch-digesting), and protease (protein-digesting) — essentially a multi-enzyme product that approximates the full digestive enzyme output of a healthy pancreas. All clinical trials on lipase for diarrhea used pancrealipase formulations, not isolated lipase. Prescription forms include Creon, Zenpep, and Pancreaze.

Are there side effects to taking lipase for diarrhea?

Side effects reported in clinical trials were generally mild. The most common include increased flatulence and, occasionally, mild constipation (when treatment is effective at firming stools). No serious adverse events were reported in the 2011 IBS-D pilot or the 2018 pediatric trial. At very high doses in pediatric cystic fibrosis patients, fibrosing colonopathy has been reported, but this is not a concern at standard therapeutic doses.

How much lipase is needed to resolve steatorrhea?

Clinical data from EPI trials suggests 18,000 to 30,000 USP units of lipase per meal as the threshold for resolving steatorrhea (fatty diarrhea) when delivered properly to the small intestine via enteric-coated capsules. Snacks typically require half this amount. Most OTC digestive enzyme supplements fall significantly below this dose.

Can I use lipase tea or natural lipase foods to treat diarrhea?

There are no clinical trials demonstrating that lipase tea diarrhea remedies or food-sourced natural lipase deliver meaningful clinical benefit for fat malabsorption-driven diarrhea. Natural lipase sources provide quantities far below therapeutic doses, and the enzyme activity is often degraded by stomach acid. These approaches may provide mild complementary digestive support but should not replace evidence-based enzyme therapy for documented fat malabsorption.

Is pancrealipase available over the counter?

In the United States, prescription-strength pancrealipase (Creon, Zenpep, Pancreaze, etc.) requires a prescription. OTC digestive enzyme supplements containing lipase, amylase, and protease are widely available but at doses significantly below the prescription therapeutic range. If you suspect EPI or significant fat malabsorption, evaluation by a gastroenterologist and fecal elastase testing is the appropriate first step.

What is the best lipase for diarrhea in IBS-D?

Based on the available clinical trial evidence, the best-studied intervention for IBS-D with postprandial symptoms is a pancrealipase formulation containing lipase, amylase, and protease in enteric-coated capsules, taken with meals. The 2011 pilot trial provides the primary support for this use. No specific commercial product has been confirmed as superior in a head-to-head IBS-D trial.

Is there a lipase for diarrhea clinical trial I can participate in?

Active clinical trials can be searched at ClinicalTrials.gov using terms such as "pancreatic enzyme supplementation," "pancrealipase," "EPI," or "IBS-D." Patients interested in participating in research should discuss eligibility with their gastroenterologist.

---

16. Clinical Summary and Key Takeaways

This has been a detailed review, so here is a concise summary of the most important clinical conclusions from the available trial evidence:

What the Evidence Supports

✅ Pancrealipase (PERT) is effective for EPI-related diarrhea — strongly supported by multiple randomized controlled trials showing reduced stool frequency (1.2 fewer stools per day), increased stool firmness, elimination of watery stools, and 33% more patients achieving normal stools.

✅ Pancrealipase reduced postprandial IBS-D symptoms in a 2011 pilot trial — 61% of patients preferred pancrealipase over placebo; all four measured symptoms improved significantly at p≤0.001 in the active treatment group.

✅ Pancreatic enzyme supplementation shortened persistent diarrhea duration in children by 7 days in a 2018 randomized trial (p=0.019).

✅ RELiZORB immobilized lipase produced a 68% reduction in 24-hour diarrhea incidence and 0% diarrhea incidence at Day 90 in patients on enteral nutrition with fat malabsorption.

✅ 18,000–30,000 USP lipase units per meal is the evidence-supported dosage threshold for resolving steatorrhea in EPI.

✅ Safety profile is favorable — no serious adverse events were reported in any of the three non-EPI trials; mild flatulence and constipation are the most common side effects.

What the Evidence Does Not Support

❌ Lipase supplementation for diarrhea without an underlying fat malabsorption component.

❌ Lipase tea, natural lipase foods, or herbal remedies as substitutes for clinical enzyme therapy.

❌ Generalized anti-diarrheal use of OTC lipase supplements without identification of the diarrhea mechanism.

❌ Assuming that OTC lipase supplement doses are equivalent to clinical trial doses for EPI or significant steatorrhea.

The Clinical Bottom Line

The question "does lipase help diarrhea" has a correct and evidence-based answer: yes, when the diarrhea is caused by fat malabsorption due to insufficient lipase activity. In EPI this is well-established. In IBS-D with postprandial symptoms and probable fat malabsorption, there is promising pilot evidence. In pediatric persistent diarrhea, a randomized trial showed meaningful benefit. In diarrhea without a fat malabsorption component, the rationale and evidence do not exist.

If you have chronic, postprandial diarrhea — particularly if your stools are greasy, foul-smelling, difficult to flush, or accompanied by weight loss — this pattern is consistent with fat malabsorption and warrants clinical evaluation. Fecal elastase testing, a non-invasive stool test, can screen for EPI. A gastroenterologist can guide appropriate PERT dosing if indicated.

If you are otherwise healthy and experiencing occasional diarrhea without these features, a lipase supplement is unlikely to be your solution, and the clinical trials reviewed here do not provide a basis for recommending it.

This article is for informational and educational purposes only. It does not constitute medical advice. Always consult a qualified healthcare provider before starting any new supplement or treatment for gastrointestinal symptoms.

---

---

References

1. Suarez FL, Savaiano D, Arbisi P, Levitt MD. "Tolerance to the daily ingestion of two cups of milk by individuals claiming lactose intolerance." / Placek W et al. PMC3009417: Pilot study: a randomised, double blind, placebo controlled trial of pancrealipase for the treatment of postprandial irritable bowel syndrome-diarrhoea. Functional Gastroenterology, 2011.

1. The same pilot study published in Function in Gastroenterology (FG), providing the primary results summary. 2011.

1. Randomized clinical trial to evaluate the effects of pancreatic enzyme supplementation in persistent diarrhea. Asian Pacific Journal of Clinical Nutrition (APJCN). 2018.

1. RELiZORB Immobilized Lipase Cartridge clinical data. Trial NCT03530852. Available at ClinicalTrials.gov.

1. Pooled EPI pancrelipase randomized trial data (stool frequency and stool character endpoints). Post-2018.

1. Domínguez-Muñoz JE. "Pancreatic exocrine insufficiency: Diagnosis and treatment." Journal of Gastroenterology and Hepatology. 2011.

1. Löhr JM, et al. "United European Gastroenterology evidence-based guidelines for the diagnosis and therapy of chronic pancreatitis (HaPanEU)." United European Gastroenterology Journal. 2017.

1. DiMagno EP, et al. "Relations between pancreatic enzyme outputs and malabsorption in severe pancreatic insufficiency." New England Journal of Medicine. 1973.

1. Whitcomb DC, Lowe ME. "Human pancreatic digestive enzymes." Digestive Diseases and Sciences. 2007.

1. U.S. Food and Drug Administration. "Pancreatic Enzyme Products (PEPs): Approved Products." FDA.gov.

---